<DOC>
	<DOCNO>NCT02743065</DOCNO>
	<brief_summary>The purpose multicenter registry gather safety , efficacy survival data advance HCC patient treat HepaSphere China order evaluate application HepaSphere deTACE treat advanced HCC patient</brief_summary>
	<brief_title>HepaSphere Chemoembolization Advanced HCC Patients : Safety &amp; Efficacy Registry China</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Age 18 old 2 . Patient sign informed consent 3 . Patient must diagnosis hepatocellular cancer least one follow method : 1 . Histological confirmation 2 . Classic image characteristic HCC : Early enhancement ( Arterial hypervascularity ) Venous Delayed phase washout multidetector contrast enhance compute tomography ( CT ) scan / dynamic contrastenhanced magnetic resonance imaging ( MRI ) imaging . Either CT/ MRI show least one solid liver lesion ≥ 2 cm describe image characteristic HCC . In case liver lesion 1 2 cm , CT MRI image perform order confirm image characteristic HCC . 4 . At time study entry . 1 . Patients suitable ablation due lesion location may enrol 2 . Patients HCC recurrence suitable resection ablation maybe enrol 5 . Patient MUST BCLC stage C meet follow criterion : Stage ChildPugh A B AND Performance status ECOG ≤ 2 WITH Vascular Invasion WITHOUT Vascular invasion 6 . Patient life expectancy least 6 month 1 . Current previous treatment chemo radiation therapy sorafenib 2 . Previous treatment transarterial chemoembolization ( TACE ) 3 . Patients current history cancer except nonmelanomatous skin cancer 4 . Female patient pregnant , breastfeeding , premenopausal use effective method contraceptive 5 . Performance status ECOG &gt; 2 6 . ChildPugh Class C 7 . Occlusive tumor thrombus main portal trunk 8 . Active gastrointestinal bleeding 9 . Evidence uncorrectable bleed diathesis 10 . ExtraHepatic spread HCC 11 . &gt; 50 % tumor involvement liver 12 . Infiltrative HCC 13 . Encephalopathy adequately control medically 14 . Presence ascites control medically 15 . Any contraindication MRI/ CT ( eg . metallic implant ) 16 . Allergy contrast medium manage prophylaxis 17 . Any contraindication arteriography 18 . Any contraindication doxorubicin administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HepaSphere</keyword>
</DOC>